Galapagos will collaborate with AstraZeneca via its service division BioFocus DPI. Under the terms of the agreement, BioFocus DPI will perform hit-to-lead medicinal chemistry services for AstraZeneca’s respiratory and inflammatory drug discovery programs. As a result of the alliance, Galapagos is set to receive E650,000.
“We are very pleased with this initial contract to support AstraZeneca in developing novel drugs,” said Onno van de Stolpe, CEO of Galapagos. “Our world-class medicinal chemistry expertise within BioFocus DPI will be of great use in this new collaboration and establish the basis for a potentially long-term relationship.”
“We chose to work with BioFocus DPI because of their reputation and ability in modern lead generation methodologies,” added Dr Lars-Erik Arvidsson, vice president of R&D Lund, AstraZeneca.